BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner to Present at BTIG’s Inaugural “Emerging Tech...
September 19 2014 - 9:00AM
Business Wire
OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT:
BTX), today announced that Chief Executive Officer Joseph Wagner,
Ph.D. is scheduled to present at the inaugural BTIG Emerging
Technologies in Healthcare Diagnostics Symposium being held
September 29-30, 2014 at The Benjamin Hotel in New York City. As
part of the symposium, leading diagnostic companies will present on
a series of thematic panels to familiarize attendees with the
diagnostic space, associated technologies, and foster an
understanding of how the tools work and why they should be adopted.
Participants in the conference include publicly-traded companies as
well as companies that, like OncoCyte, are not yet publicly
traded.
During the symposium, Dr. Wagner will participate on two
thematic panels. The first panel, entitled “Symptomatic Oncology –
Innovations in Blood Testing” will convene at 1:10 PM on Monday,
September 29. The second panel, entitled “Changing Screening
Paradigms from Scratch” will convene at 3:40 PM on Tuesday,
September 30. During the presentations and as part of the ensuing
discussions, Dr. Wagner may provide an update on the clinical
development of OncoCyte’s PanC-Dx™ products. In addition to his
appearance at the conference, Dr. Wagner will also be meeting with
investors in other meetings in New York beginning next week.
BioTime plans to file a Form 8-K with the Securities and Exchange
Commission next week that will include the OncoCyte presentation
materials that will be used in these investor meetings.
PanC-Dx™ is a class of non-invasive cancer diagnostics based on
OncoCyte’s proprietary set of cancer markers, which were discovered
by company scientists through an analysis of broad gene expression
patterns in numerous cancer types. OncoCyte is currently sponsoring
four clinical studies of PanC-Dx™ in bladder, breast, and lung
cancer, of which approximately 1300, 800 and 750 subjects are
expected to be enrolled, respectively. The data on the majority of
these studies is expected to be collected and analyzed by the end
of 2014.
About OncoCyte Corporation
OncoCyte, a majority-owned subsidiary of BioTime, Inc., is
developing novel products for the diagnosis and treatment of cancer
in order to improve the quality and length of life of cancer
patients. Based on large unmet need, market size, and data
generated thus far from patient sample screening, OncoCyte is
initially focusing its efforts on developing PanC-Dx™ diagnostic
products for use in detecting breast, bladder, and lung cancers.
PanC-Dx™ is a class of non-invasive cancer diagnostics based on a
proprietary set of cancer markers characterized, in part, by broad
gene expression patterns in numerous cancer types. The PanC-Dx™
biomarkers were discovered as a result of ongoing research within
OncoCyte and BioTime on the gene expression patterns associated
with embryonic development. This research has demonstrated that
many of the same genes associated with normal growth during
embryonic development are abnormally reactivated by cancer cells.
These genes regulate such diverse processes as cell proliferation,
cell migration and blood vessel formation. Many of these genes have
not been previously associated with cancer. Moreover, expression of
a large subset of these genes is conserved across numerous cancer
types (e.g. cancers of the breast, colon, ovaries, etc.),
suggesting these genes may control fundamental processes during
cancer growth and progression. In addition to their potential value
in developing diagnostic biomarkers, an understanding of the
pattern of expression of these genes may also enable the
development of powerful new cancer therapeutics that target rapidly
proliferating cancer cells.
About BioTime
BioTime is a biotechnology company engaged in research and
product development in the field of regenerative medicine.
Regenerative medicine refers to therapies based on stem cell
technology that are designed to rebuild cell and tissue function
lost due to degenerative disease or injury. BioTime’s focus is on
pluripotent stem cell technology based on human embryonic stem
(“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and
iPS cells provide a means of manufacturing every cell type in the
human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of
proprietary PureStem® progenitors, HyStem® hydrogels, culture
media, and differentiation kits. BioTime is developing Renevia™ (a
HyStem® product) as a biocompatible, implantable hyaluronan and
collagen-based matrix for cell delivery in human clinical
applications, and is planning to initiate a pivotal clinical trial
around Renevia™, in 2014. In addition, BioTime has developed
Hextend®, a blood plasma volume expander for use in surgery,
emergency trauma treatment and other applications. Hextend® is
manufactured and distributed in the U.S. by Hospira, Inc. and in
South Korea by CJ HealthCare Corporation, under exclusive licensing
agreements.
BioTime is also developing stem cell and other products for
research, therapeutic, and diagnostic use through its
subsidiaries:
- Asterias Biotherapeutics, Inc.
is developing pluripotent stem-cell based therapies in neurology
and oncology, including AST-OPC1 oligodendrocyte progenitor cells
in spinal cord injury, multiple sclerosis and stroke, and AST-VAC2,
an allogeneic dendritic cell-based cancer vaccine. Asterias trades
publicly under the symbol ASTY.
- BioTime Asia, Ltd., a Hong Kong
company, may offer and sell products for research use for BioTime’s
ESI BIO Division.
- Cell Cure Neurosciences Ltd. is
an Israel-based biotechnology company focused on developing stem
cell-based therapies for retinal and neurological disorders,
including the development of retinal pigment epithelial cells for
the treatment of macular degeneration, and treatments for multiple
sclerosis.
- ESI BIO is the research and
product marketing division of BioTime, providing stem cell
researchers with products and technologies to enable them to
translate their work into the clinic, including PureStem®
progenitors and HyStem® hydrogels.
- LifeMap Sciences, Inc. markets,
sells, and distributes GeneCards®, the leading human gene database,
as part of an integrated database suite that also includes the
LifeMap Discovery® database of embryonic development, stem cell
research, and regenerative medicine, and MalaCards, the human
disease database.
- LifeMap Solutions, Inc. is a
subsidiary of LifeMap Sciences focused on developing mobile health
(mHealth) products.
- OncoCyte Corporation is
developing products and technologies to diagnose and treat cancer,
including PanC-Dx™, with three clinical trials currently
underway.
- OrthoCyte Corporation is
developing therapies to treat orthopedic disorders, diseases and
injuries.
- ReCyte Therapeutics, Inc. is
developing therapies to treat a variety of cardiovascular and
related ischemic disorders, as well as products for research using
cell reprogramming technology.
BioTime common shares are traded on the NYSE MKT ticker BTX. For
more information, please visit www.biotimeinc.com or connect with
the company on Twitter, LinkedIn, Facebook, YouTube, and
Google+.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime's Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com
BioTime, Inc.Judith Segall, 510-521-3390, ext
301jsegall@biotimemail.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024